Paul Wotton

BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.

SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom.

Eurand NV develops pharmaceutical and biopharmaceutical products using proprietary drug formulation technologies. The company was founded in 1984 and is headquartered in Amsterdam, the Netherlands.

Penwest Pharmaceuticals Co. is a speciality pharmaceutical company focused on the development and commercialisation of therapies for the treatment of neurological disorders. Its oral controlled release technologies are also available for the development and commercialisation of products in multiple therapeutic areas. The company was founded in 1991 and is headquartered in Patterson, NY.

Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA.

Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Kytopen Corp. engages in the provision of technology solutions. It develops genetically engineered cells that modifies microorganisms. The company was founded by Paulo A. Gracia and Cullen R. Buie in 2017 and is headquartered in Cambridge, MA.

Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA.

Dimension Inx LLC operates as a regenerative medicine company. It offers 3D-Printing for tissue and organ repair and regeneration. The company was founded by Ramille N. Shah, Caralynn Nowinski Collens and Adam E. Jakus in 2016 and is headquartered in Chicago, IL.